Feiko Olijve @Feiko_0
Pfizer: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS.
https://media.tghn.org/med...
8.3.5. - Exposure During Pregnancy or Breastfeeding, and Occupational Exposure.

The following is detailed, and far worse. This is universal, and very bad.
https://fromthetrencheswor...

Pfizer: Protocol Title: Genetherapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [adeno-associated viral vector with human factor IX gene] insubjects with hemophilia B
.GOV Prot_001: https://clinicaltrials.gov...
09:27 PM - May 01, 2021
Only people mentioned by Feiko_0 in this post can reply

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Feiko Olijve, click on at the bottom under it